Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 8/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | DHODH | Q02127 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.59 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717093 | 0.87 | ADCY8 (0.76) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1898948 | 0.86 | STAT3 (1.00) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1898939 | 0.85 | STAT3 (0.82) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1899281 | 0.85 | STAT3 (0.78) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1897621 | 0.85 | STAT3 (0.77) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL15015470 | 0.82 | STAT3 (0.88) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1900296 | 0.81 | STAT3 (0.79) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1898982 | 0.80 | STAT3 (0.77) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1901610 | 0.80 | STAT3 (0.77) | STAT3KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL1903465 | 0.80 | STAT3 (0.80) | STAT3KDM4ELMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | disclosed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | STAT3 1830/4885KDM4E 916/4885LMNA 1893/4885 |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | STAT3 1/4885KDM4E 532/4885LMNA 4766/4885 |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | STAT3 1830/4885KDM4E 916/4885LMNA 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.